Immunovant, Inc.
IMVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764013
In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.
Q3 2021 vs. Q2 2021
How the institutions holding Immunovant, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 110 | 119 | +9 |
| Shares | 38.6M | 33.8M | −4.77M (−12.4%) |
| Value | $407.5M | $293.6M | −$113.9M (−28.0%) |
New holders (26)
Institutions that held Immunovant, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
Sold out (17)
Institutions that held Immunovant, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| BVF Inc | 1,273,516 | $13.5M |
| Boxer Capital, LLC | 1,000,000 | $10.6M |
| One Fin Capital Management LP | 612,497 | $6.47M |
| Vivo Capital, LLC | 532,847 | $5.63M |
| Altium Capital Management LP | 335,041 | $3.54M |
| Peregrine Capital Management LLC | 291,456 | $3.08M |
| PDT Partners, LLC | 135,700 | $1.43M |
| Eversept Partners, LP | 110,183 | $1.16M |
| Ionic Capital Management LLC | 70,000 | $740.0K |
| Qube Research & Technologies Ltd | 37,453 | $396.0K |
| Algert Global LLC | 28,710 | $303.0K |
| SEI Investments Co | 20,151 | $213.0K |
| Parallel Advisors, LLC | 14,262 | $151.0K |
| Bridgefront Capital, LLC | 13,612 | $144.0K |
| Walleye Trading LLC | 11,737 | $124.0K |
| Captrust Financial Advisors | 351 | $4.00K |
| Berman Capital Advisors, LLC | 206 | $2.00K |